Tiverton Asset Management’s Acceleron Pharma XLRN Stock Holding History

Tiverton Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$162K	Sell	4,101 -502	-11%	-$21.8K	0.01%	581
2019 Q2	$189K	Sell	4,603 -33,097	-88%	-$1.37M	0.01%	566
2019 Q1	$1.76M	Hold	37,700	–	–	0.08%	179
2018 Q4	$1.64M	Sell	37,700 -26,425	-41%	-$1.32M	0.1%	138
2018 Q3	$3.67M	Sell	64,125 -1,018	-2%	-$50K	0.18%	100
2018 Q2	$3.16M	Buy	65,143 +3,296	+5%	+$120K	0.16%	110
2018 Q1	$2.42M	Buy	+61,847	New	+$2.63M	0.17%	108

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Tiverton Asset Management's XLRN Position: Q3 2019 in Review

Tiverton Asset Management reduced its Acceleron Pharma (XLRN) stake by 11% in Q3 2019, selling an estimated $21.8K and leaving 4,101 shares worth $162K. The position accounts for 0.01% of the portfolio, ranked #581.

Tiverton Asset Management first reported a position in XLRN in Q1 2018 and has held it in 7 quarters since. The position peaked at $3.67M in Q3 2018. 172 funds tracked by Wall St. Rank hold XLRN as of Q3 2019.

Tiverton Asset Management held 4,101 shares of Acceleron Pharma worth $162K as of Q3 2019.
Tiverton Asset Management sold 502 Acceleron Pharma shares in Q3 2019, an estimated $21.8K.
Acceleron Pharma made up 0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #581 holding.
Tiverton Asset Management first reported a position in Acceleron Pharma in Q1 2018 and has held it in 7 quarters since.
Tiverton Asset Management's Acceleron Pharma position peaked at $3.67M in Q3 2018.
172 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.